Immune suppression in renal cell carcinoma

Seminars in Cancer Biology

Volumn 17, Issue 4, 2007, Pages 330-343

  Frankenberger, Bernhard ^a   Noessner, Elfriede ^a   Schendel, Dolores J ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cytokine therapies; Immune suppression; Immune therapies; Renal cell carcinoma; Tumor escape

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CANCER VACCINE; CD69 ANTIGEN; CHEMOKINE RECEPTOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; GAMMA INTERFERON; GANGLIOSIDE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; T LYMPHOCYTE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIGEN EXPRESSION; APOPTOSIS; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; DRUG MEGADOSE; HUMAN; IMMUNE SYSTEM; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 34547653931     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.06.004     Document Type: Review

References (135)

1. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20 4 (1997) 416-418
2. Sanchez-Ortiz R.F., Tannir N., Ahrar K., and Wood C.G. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol 170 1 (2003) 178-179
3. Schendel D.J., Oberneder R., Falk C.S., Jantzer P., Kressenstein S., Maget B., et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 75 (1997) 400-413
4. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 19 335(12) (1996) 865-875
5. Parton M., Gore M., and Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24 35 (2006) 5584-5592
6. Franzke A., Buer J., Probst-Kepper M., Lindig C., Framzle M., Schrader A.J., et al. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16 5 (2001) 401-409
7. Ellerhorst J.A., Hildebrand W.H., Cavett J.W., Fernandez-Vina M.A., Hodges S., Poindexter N., et al. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol 169 6 (2003) 2084-2088
8. Kowalczyk D., Skorupski W., Kwias Z., and Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 80 4 (1997) 543-547
9. Van den Hove L.E., Van Gool S.W., Van Poppel H., Baert L., Coorevits L., Van Damme B., et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 109 3 (1997) 501-509
10. Schleypen J.S., Von Geldern M., Weiss E.H., Kotzias N., Rohrmann K., Schendel D.J., et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 106 6 (2003) 905-912
11. Gati A., Da Rocha S., Guerra N., Escudier B., Moretta A., Chouaib S., et al. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 109 3 (2004) 393-401
12. Cozar J.M., Canton J., Tallada M., Concha A., Cabrera T., Garrido F., et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 54 9 (2005) 858-866
13. Schleypen J.S., Baur N., Kammerer R., Nelson P.J., Rohrmann K., Grone E.F., et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12 3 Pt 1 (2006) 718-725
14. Thurnher M., Radmayr C., Ramoner R., Ebner S., Bock G., Klocker H., et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68 1 (1996) 1-7
15. Troy A.J., Summers K.L., Davidson P.J., Atkinson C.H., and Hart D.N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4 3 (1998) 585-593
16. Schwaab T., Schned A.R., Heaney J.A., Cole B.F., Atzpodien J., Wittke F., et al. In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162 2 (1999) 567-573
17. Verra N., de Jong D., Bex A., Batchelor D., Dellemijn T., Sein J., et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 48 3 (2005) 527-533
18. Alexander R.B., Fitzgerald E.B., Mixon A., Carter C.S., Jakobsen M., Cohen P.A., et al. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J Immunother Emphasis Tumor Immunol 17 1 (1995) 39-46
19. Angevin E., Kremer F., Gaudin C., Hercend T., and Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 72 3 (1997) 431-440
20. Shabtai M., Ye H., Frischer Z., Martin J., Waltzer W.C., and Malinowski K. Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J Urol 168 5 (2002) 2216-2219
21. Jantzer P., and Schendel D.J. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 58 14 (1998) 3078-3086
22. Dorrschuck A., Schmidt A., Schnurer E., Gluckmann M., Albrecht C., Wolfel C., et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 104 8 (2004) 2591-2599
23. Dengjel J., Nastke M.D., Gouttefangeas C., Gitsioudis G., Schoor O., Altenberend F., et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12 (2006) 4163-4170
24. Tassi E., Facchinetti V., Seresini S., Borri A., Dell'antonio G., Garavaglia C., et al. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology. Clin Cancer Res 12 16 (2006) 4949-4957
25. Falk C.S., Noessner E., Weiss E.H., and Schendel D.J. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res 62 2 (2002) 480-487
26. von Geldern M., Simm B., Braun M., Weiss E.H., Schendel D.J., and Falk C.S. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I. Eur J Immunol 36 9 (2006) 2347-2358
27. Garrido F., and Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83 (2001) 117-158
28. Mattijssen V., Van Moorselaar J., De Mulder P.H., Schalkwijk L., and Ruiter D.J. Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy. J Immunother 12 1 (1992) 64-69
29. Ohmori T., Okada K., Arita N., Watanabe Y., Miyazaki T., and Tabei R. Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol Histopathol 10 4 (1995) 789-794
30. Ibrahim el C., Allory Y., Commo F., Gattegno B., Callard P., and Paul P. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am J Pathol 162 2 (2003) 501-508
31. Maleno I., Lopez Nevot M.A., Seliger B., and Garrido F. Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas. Int J Cancer 109 4 (2004) 636-638
32. Romero J.M., Aptsiauri N., Vazquez F., Cozar J.M., Canton J., Cabrera T., et al. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 68 4 (2006) 303-310
33. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003;52(1):1-9 [Epub December 10, 2002].
34. Luboldt H.J., Kubens B.S., Rubben H., and Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56 4 (1996) 826-830
35. Murakami Y., Kanda K., Yokota K., Kanayama H., and Kagawa S. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol Urol 5 3 (2001) 113-119
36. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21 9 (2000) 455-464
37. Gouttefangeas C., Stenzl A., Stevanovic S., and Rammensee H.G. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56 1 (2007) 117-128
38. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96 12 (1999) 6879-6884
39. Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Ruebben H., Drexler I., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 14 (2003) 4107-4111
40. Bukur J., Malenica B., Huber C., and Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol 64 11 (2003) 1081-1092
41. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54 8 (2005) 721-728
42. Egeter O., Mocikat R., Ghoreschi K., Dieckmann A., and Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 60 6 (2000) 1515-1520
43. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 23 5 (2005) 413-419
44. van Bezooijen R.L., Goey H., Stoter G., Hermans J., and Fleuren G.J. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2. Cancer Immunol Immunother 43 5 (1996) 293-298
45. Rayman P., Uzzo R.G., Kolenko V., Bloom T., Cathcart M.K., Molto L., et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J Sci Am 6 Suppl. 1 (2000) S81-S87
46. Wang Q., Redovan C., Tubbs R., Olencki T., Klein E., Kudoh S., et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 61 6 (1995) 780-785
47. Storkel S., Keymer R., Steinbach F., and Thoenes W. Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res 378 (1992) 217-223
48. Zhang J., Chen Y., Li J., Zhang R., Wu Y., Zou L., et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J Nephrol 19 4 (2006) 429-438
49. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101 49 (2004) 17174-17179
50. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104 10 (2005) 2084-2091
51. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103 27 (2006) 10391-10396
52. Kudoh S., Redovan C., Rayman P., Edinger M., Tubbs R.R., Novick A., et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother 20 6 (1997) 479-487
53. Voskoboinik I., Smyth M.J., and Trapani J.A. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6 12 (2006) 940-952
54. Steger G.G., Gnant M.F., Djavanmard M.P., Mader R.M., Jakesz R., Pierce W., et al. The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma. J Cancer Res Clin Oncol 123 6 (1997) 317-324
55. Trinchieri G. Biology of natural killer cells. Adv Immunol 47 (1989) 187-376
56. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 2 (2003) 133-146
57. Nakagomi H., Pisa P., Pisa E.K., Yamamoto Y., Halapi E., Backlin K., et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 63 3 (1995) 366-371
58. Onishi T., Ohishi Y., Goto H., Tomita M., and Abe K. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood. BJU Int 87 9 (2001) 755-759
59. Uzzo R.G., Rayman P., Kolenko V., Clark P.E., Cathcart M.K., Bloom T., et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 104 6 (1999) 769-776
60. Rayman P., Wesa A.K., Richmond A.L., Das T., Biswas K., Raval G., et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10 18 Pt 2 (2004) 6360S-6366S
61. Biswas K., Richmond A., Rayman P., Biswas S., Thornton M., Sa G., et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 66 13 (2006) 6816-6825
62. Wahl S.M. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 19 1 (2007) 55-62
63. Knoefel B., Nuske K., Steiner T., Junker K., Kosmehl H., Rebstock K., et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 17 2 (1997) 95-102
64. Lahn M., Fisch P., Kohler G., Kunzmann R., Hentrich I., Jesuiter H., et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol 35 1 (1999) 70-80
65. Mitropoulos D., Kiroudi A., Christelli E., Serafetinidis E., Zervas A., Anastasiou I., et al. Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res 32 5 (2004) 317-322
66. Zou W., and Regulatory. T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 4 (2006) 295-307
67. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 8 (2005) 1075-1085
68. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol Immunother 53 10 (2004) 865-878
69. Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53 23 (1993) 5613-5616
70. Tartour E., Latour S., Mathiot C., Thiounn N., Mosseri V., Joyeux I., et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63 2 (1995) 205-212
71. Cardi G, Heaney JA, Schned AR, Phillips DM, Branda MT, Ernstoff MS. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res 1997;57(16):3517-9 [Erratum in: Cancer Res 1997;57(21):4973].
72. Bukowski R.M., Rayman P., Uzzo R., Bloom T., Sandstrom K., Peereboom D., et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4 10 (1998) 2337-2347
73. Ochoa A.C., Zea A.H., Hernandez C., and Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13 2 (2007) 721s-726s
74. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4 9 (2004) 675-687
75. Donskov F., Hokland M., Marcussen N., Torp Madsen H.H., and von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24 13 (2006) 1997-2005
76. Donskov F., Bennedsgaard K.M., Von Der Maase H., Marcussen N., Fisker R., Jensen J.J., et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 87 2 (2002) 194-201
77. Donskov F., Hokland M., Marcussen N., Torp Madsen H.H., and von der Maase H. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma-results from a randomised phase II trial. Br J Cancer 94 2 (2006) 218-226
78. Kawata N., Ono M., Kodama M., Yamanaka Y., Hirakata H., Hirano D., et al. A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes. Hinyokika Kiyo 41 1 (1995) 21-26
79. Toliou T., Stravoravdi P., Polyzonis M., and Vakalikos J. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study. Eur Urol 29 2 (1996) 252-256
80. Hofmann R., Lehmer A., Reidel G., Schutz W., and Bottger I. Natural killer cells in patients with renal cell cancer. Urol Int 40 5 (1985) 251-256
81. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 6908 (2002) 734-738
82. Holdenrieder S., Stieber P., Peterfi A., Nagel D., Steinle A., and Salih H.R. Soluble MICA in malignant diseases. Int J Cancer 118 3 (2006) 684-687
83. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18 3 (2006) 349-356
84. Schoof D.D., Terashima Y., Peoples G.E., Goedegebuure P.S., Andrews J.V., Richie J.P., et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 150 1 (1993) 114-123
85. Elsasser-Beile U., Kolble N., Grussenmeyer T., Schultze-Seemann W., Wetterauer U., Gallati H., et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol 19 6 (1998) 470-476
86. Kondo T., Nakazawa H., Ito F., Hashimoto Y., Osaka Y., Futatsuyama K., et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97 8 (2006) 780-786
87. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., and Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161 2 (1998) 927-932
88. Maeurer M.J., Martin D.M., Castelli C., Elder E., Leder G., Storkus W.J., et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 41 2 (1995) 111-121
89. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17 2 (2005) 180-186
90. Lauerova L., Dusek L., Simickova M., Rovny F., Spurny V., Rovny A., et al. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy. Neoplasma 46 3 (1999) 141-149
91. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 12 (2005) 3623-3633
92. Cesana G.C., DeRaffele G., Cohen S., Moroziewicz D., Mitcham J., Stoutenburg J., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 7 (2006) 1169-1177
93. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196 5 (2002) 619-628
94. Nakamura E., Megumi Y., Kobayashi T., Kamoto T., Ishitoya S., Terachi T., et al. Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res 8 8 (2002) 2620-2625
95. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 6 6 (2006) 476-483
96. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4 12 (2004) 941-952
97. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 4 (2005) 263-274
98. Menetrier-Caux C., Bain C., Favrot M.C., Duc A., and Blay J.Y. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 79 1 (1999) 119-130
99. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 12 (1998) 4778-4791
100. Kusmartsev S., and Gabrilovich D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25 3 (2006) 323-331
101. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5 11 (1999) 1249-1255
102. Cabillic F., Bouet-Toussaint F., Toutirais O., Rioux-Leclercq N., Fergelot P., de la Pintiere C.T., et al. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp Immunol 146 3 (2006) 518-523
103. Wersall P.J., Blomgren H., Pisa P., Lax I., Kalkner K.M., and Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45 4 (2006) 493-497
104. Santini S.M., Lapenta C., and Belardelli F. Type I interferons as regulators of the differentiation/activation of human dendritic cells: methods for the evaluation of IFN-induced effects. Meth Mol Med 116 (2005) 167-181
105. Tosi D., Valenti R., Cova A., Sovena G., Huber V., Pilla L., et al. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 172 9 (2004) 5363-5370
106. Frankenberger B., Regn S., Geiger C., Noessner E., Falk C.S., Pohla H., et al. Cell-based vaccines for metastatic renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 3 (2005) 166-174
107. Beignon A.S., Skoberne M., and Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 4 10 (2003) 939-941
108. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 10 (2003) 1009-1015
109. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 5 (2004) 336-347
110. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 12 (1999) 1365-1369
111. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800 [Epub 2002 Jun 24, Erratum in: Nat Med 2002;8(9):1039].
112. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 3 (2001) 261-268
113. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 84 1 (2002) 57-62
114. Carter L., Fouser L.A., Jussif J., Fitz L., Deng B., Wood C.R., et al. PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32 3 (2002) 634-643
115. Frankenberger B., Pohla H., Noessner E., Willimsky G., Papier B., Pezzutto A., et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 11 5 (2005) 1733-1742
116. Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63 19 (2003) 6501-6505
117. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 3 (2005) 1089-1096
118. Beil W.J., Fureder W., Wiener H., Grossschmidt K., Maier U., Schedle A., et al. Phenotypic and functional characterization of mast cells derived from renal tumor tissues. Exp Hematol 26 2 (1998) 158-169
119. Donskov F., Bennedsgaard K.M., Hokland M., Marcussen N., Fisker R., Madsen H.H., et al. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53 8 (2004) 729-739
120. Hamada I., Kato M., Yamasaki T., Iwabuchi K., Watanabe T., Yamada T.H., et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 22 6C (2002) 4281-4284
121. Hemmerlein B., Markus A., Wehner M., Kugler A., Zschunke F., and Radzum H.J. Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother 49 9 (2000) 485-492
122. Agarwala S.S., and Sabbagh M.H. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment. Expert Opin Biol Ther 1 5 (2001) 869-879
123. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 8 (2005) 3044-3048
124. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66 18 (2006) 9299-9307
125. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116 2 (2006) 485-494 [Epub January 19, 2006]
126. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., and Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108 1 (2006) 253-261
127. Schoffski P., Dumez H., Clement P., Hoeben A., Prenen H., Wolter P., et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17 8 (2006) 1185-1196
128. Engels B., Noessner E., Frankenberger B., Blankenstein T., Schendel D.J., and Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 16 7 (2005) 799-810
129. Sommermeyer D., Neudorfer J., Weinhold M., Leisegang M., Engels B., Noessner E., et al. Designer T cells by T cell receptor replacement. Eur J Immunol 36 11 (2006) 3052-3059
130. Schendel D.J. Dendritic cell vaccine strategies for renal cell carcinoma. Expert Opin Biol Ther 7 2 (2007) 221-232
131. Noessner E., Falk C.S., and Schendel D.J. In: Hiddemann W., Büchner T., Ritter J., Unterhalt M., and Haferlach T. (Eds). InteCrferon alpha and gamma differentially alter the susceptibility of tumor cells to lysis by MHC-restricted and non-MHC-restricted cytotoxic effector cells (2003), Springer Verlag, Berlin, Heidelberg, New York 497-503
132. Schendel D.J., Falk C.S., Nossner E., Maget B., Kressenstein S., Urlinger S., et al. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity. Gene Ther 7 11 (2000) 950-959
133. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3 12 (2004) 1011-1022
134. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 7054 (2005) 1186-1190
135. Djafarzadeh R., Noessner E., Engelmann H., Schendel D.J., Notohamiprodjo M., von Luettichau I., et al. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 25 10 (2006) 1496-1508